Koreki, Akihiro
Sado, Mitsuhiro
Mitsukura, Yasue
Tachimori, Hisateru
Kubota, Anna
Kanamori, Yoshiaki
Uchibori, Manae
Usune, Shiyori
Ninomiya, Akira
Shirahama, Ryutaro
Fujimoto, Akihiro
Inabe, Kanako
Miyata, Hiroaki
Mimura, Masaru
Funding for this research was provided by:
This research was funded by Eisai Co., Ltd.
Article History
Received: 13 February 2024
Accepted: 21 August 2024
First Online: 30 September 2024
Competing interests
: MS has received honoraria from Takeda Pharmaceutical Company Ltd., Kyowa Kirin Co., Viatris Inc., Shionogi & Co., Ltd., Meiji Seika Pharma, Yoshitomiyakuhin Corporation, and Mochida Pharmaceutical outside of the submitted work. MM has received speaker’s honoraria from Biogen Japan, Byer Pharmaceutical, Daiichi Sankyo, Dainippon-Sumitomo Pharma, Demant Japan, Eisai, Eli Lilly, Fuji Film RI Pharma, Hisamitsu Pharmaceutical, H.U. Frontier, Janssen Pharmaceutical, Mochida Pharmaceutical, MSD, Mylan EPD, Nippon Chemipher, Novartis Pharma, Ono Yakuhin, Otsuka Pharmaceutical, Pfizer, Shionogi, Takeda Yakuhin, Teijin Pharma, and Viatris within the past two years. Also, he received grants from Daiichi Sankyo, Eisai, Fronteo, Shionogi, Takeda, Tanabe Mitsubishi and Tsumura within the past three years outside the submitted work. AF and KI are employees of Eisai Co., Ltd. This study was partly supported by Joint Research Grant from Eisai Co., Ltd. All other remaining authors have no conflict of interest.